Oculis Holding (OCS)

• Market cap: $1.54B
• 1 day: 2.34%
• 5 days: -8.58%
• 1 month: -7.44%
• 3 months: 37.06%
• 6 months: 53.05%
• Year to date: 33.15%
• 1 year: 41.42%
• 5 years: 144.54%
• 10 years: 144.54%
• Sector: Healthcare
• Industry: Biotechnology

About: Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

Employees: 3